How Much Did Mammoth Raise? Headquarters, Funding & Key Investors

Mammoth, a San Francisco-based CRISPR diagnostics company, has raised $271 million across multiple rounds, including a $150 million Series D led by Redmile Group and Foresite Capital. With a $1 billion valuation (as of September 2021), the company leverages Cas12 and Cas13 proteins to develop next-gen molecular diagnostics for healthcare, agriculture, and industrial applications. Backed by top investors like Mayfield, Decheng Capital, and the National Institutes of Health, Mammoth aims to redefine disease detection and gene-based therapeutics through precision CRISPR technology.

How Much Did Mammoth Raise? Funding & Key Investors

Mammoth develops a CRISPR-driven molecular diagnostics platform designed to detect DNA and RNA biomarkers quickly and accurately. Its proprietary Cas12 and Cas13 systems allow real-time detection across healthcare, agriculture, and environmental sectors. With partnerships in both research and industrial applications, Mammoth is advancing accessible, scalable diagnostic tools that integrate biotechnology, AI, and automation to transform global disease monitoring and treatment development.

What Is Mammoth and What Does It Do?

Mammoth, founded in 2017 by Trevor Martin, Lucas Harrington, Janice Chen, and Jennifer Doudna, is headquartered in San Francisco, California. The company develops a CRISPR-based molecular diagnostics platform that leverages Cas12 and Cas13 proteins to enable precise detection of DNA and RNA for medical and industrial applications.

Mammoth employs between 11 and 50 people. Its CRISPR platform powers new diagnostic modalities for disease detection, agriculture, and environmental testing. By transforming CRISPR into a commercial tool, Mammoth aims to revolutionize diagnostics, making precision testing faster, cheaper, and more scalable worldwide.

How Much Funding Has Mammoth Raised?

1. Pre-Seed Round

Amount Raised: $120K
Date: May 2017
Lead Investors: NFX
Motivation: To initiate company operations and launch foundational CRISPR research.

2. Seed Round

Amount Raised: $1.4M
Date: November 2017
Lead Investors: NFX
Motivation: To expand the founding team and enhance early-stage CRISPR platform development.

3. Series A

Amount Raised: $23M
Date: July 2018
Lead Investors: Mayfield Fund
Motivation: To scale up R&D and accelerate commercial applications of CRISPR diagnostics.

4. Series B

Amount Raised: $45M
Date: January 2020
Lead Investors: Decheng Capital
Motivation: To mature their CRISPR-based platform for therapeutic and diagnostic uses.

5. Series C

Amount Raised: $45M
Date: November 2020
Lead Investors: Foresite Capital, NFX, Redmile Group
Motivation: To scale diagnostic pipelines and expand into new therapeutic markets.

6. Series D

Amount Raised: $150M
Date: September 2021
Lead Investors: Redmile Group
Motivation: To accelerate therapeutic CRISPR programs and pursue permanent genetic cures.

Total Funding Raised: $271 Million

Current Valuation: $1 Billion (as of September 2021)

Latest Funding Date: September 2021

Key Investors

1. Redmile Group

Details: Redmile Group is a healthcare-focused investment firm specializing in the biotechnology and pharmaceutical sectors.
Investment Focus Areas: Biotech, pharmaceuticals, and healthcare innovation.
Notable Investments: Relay Therapeutics, Allogene Therapeutics.

2. Foresite Capital

Details: Foresite Capital is a leading venture capital and private equity firm supporting transformative healthcare and life sciences startups.
Investment Focus Areas: Genomics, therapeutics, diagnostics.
Notable Investments: 10x Genomics, Denali Therapeutics, Element Biosciences.

3. NFX

Details: NFX is a seed-stage venture capital firm known for backing companies with strong network effects.
Investment Focus Areas: Life sciences, AI, deep tech.
Notable Investments: Mammoth Biosciences, Lyft, DoorDash.

4. Decheng Capital

Details: Decheng Capital is a venture capital firm focusing on innovative healthcare and life sciences technologies.
Investment Focus Areas: Biotech, medical devices, diagnostics.
Notable Investments: Grail, Arcus Biosciences, Twist Bioscience.

Where Is Mammoth Headquarters?

Mammoth is headquartered in San Francisco, California, one of the world’s leading biotech and life sciences hubs. The city provides access to world-class research institutions like UC Berkeley and Stanford University, as well as a strong ecosystem of venture capital and talent, making it an ideal location for biotech innovation and CRISPR research.

What’s Next for Mammoth?

Mammoth is now transitioning from diagnostics to therapeutic CRISPR applications, focusing on permanent genetic cures and partnerships with major pharma companies. The firm aims to expand its Cas14 enzyme toolkit, enabling ultra-sensitive and multiplexed detection of genes. With sustained investor backing and cutting-edge IP from co-founder Jennifer Doudna, Mammoth is poised to lead the next era of programmable molecular medicine transforming disease detection and treatment at the genetic level.

Get Investor & Funding Insights with TexAu

TexAu helps sales and business teams uncover detailed fundraising information on companies like Mammoth. Use the platform to research investors, track funding rounds, and gather actionable insights to strengthen prospecting and business strategy.